Our Mission

The National Bleeding Disorders Foundation (NBDF) Nebraska Chapter is dedicated to finding cures for inheritable blood disorders and addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive.

News Articles

NBDF recently learned that Novo Nordisk now has 3,000 IU vial size of Rebinyn® back in stock. Rebinyn is the company's recombinant factor IX extended half-life therapy for the treatment of hemophilia B. It is indicated for the on-demand treatment and control of bleeding episodes and the management of bleeding around surgery. It is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes.

The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for IXINITY® (Medexus), a recombinant factor replacement therapy to treat patients with hemophilia B. 

The new approval expands the product indication to include the on-demand, prophylactic, and perioperative treatment of children under 12 years of age. The previous indication was limited to adults and older children more than 12 years of age.

For Immediate Release 

CONTACT:  

Carrie Strehlau and Kyla Clark 

National Bleeding Disorders Foundation 

212-382-3773 

kclark@hemophilia.org%C2%A0" title="Email for Kyla Clark">kclark@hemophilia.org 

 

National Bleeding Disorders Foundation Celebrates Five Years of Community Voices in Research 

ADVERTISEMENTS

.

Resource Links

8031 West Center Road
Suite 301
Omaha, NE 68124

© National Bleeding Disorders Foundation 2024

Crafted by Firespring